{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:08:22Z","timestamp":1790438902734,"version":"4.1.0"},"reference-count":36,"publisher":"National Academy of Sciences","issue":"10","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["2RO1CA129933"],"award-info":[{"award-number":["2RO1CA129933"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["EB008047"],"award-info":[{"award-number":["EB008047"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["2U01EB012493"],"award-info":[{"award-number":["2U01EB012493"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["DMR-1310266"],"award-info":[{"award-number":["DMR-1310266"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["ECS-0335715"],"award-info":[{"award-number":["ECS-0335715"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-12-1-0153"],"award-info":[{"award-number":["W81XWH-12-1-0153"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["16YOUN13"],"award-info":[{"award-number":["16YOUN13"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM007753"],"award-info":[{"award-number":["T32GM007753"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2018,3,6]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>Identifying predictive biomarkers of therapeutic response for melanoma patients treated with immune checkpoint inhibitors is a major challenge. By combining microfluidic enrichment for melanoma circulating tumor cells (CTCs) together with RNA-based droplet digital PCR quantitation, we have established a highly sensitive and robust platform for noninvasive, blood-based monitoring of tumor burden. Serial monitoring of melanoma patients treated with immune checkpoint inhibitors shows rapid changes in CTC score, which precede standard clinical assessment and are highly predictive of long-term clinical outcome. Early on-treatment digital monitoring of CTC dynamics may thus help identify patients likely to benefit from immune checkpoint inhibition therapy.<\/jats:p>","DOI":"10.1073\/pnas.1719264115","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T14:20:20Z","timestamp":1518790820000},"page":"2467-2472","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":118,"title":["Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy"],"prefix":"10.1073","volume":"115","author":[{"given":"Xin","family":"Hong","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"},{"name":"Division of Hematology\u2013Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kalinich","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya Todorova","family":"Kwan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Pan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"LiCausi","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Milner","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda T.","family":"Nieman","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben S.","family":"Wittner","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen","family":"Ho","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Kapur","sequence":"additional","affiliation":[{"name":"Center for Bioengineering in Medicine, Massachusetts General Hospital and Shriners Hospital for Children, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"},{"name":"Division of Hematology\u2013Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"},{"name":"Division of Hematology\u2013Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lecia V.","family":"Sequist","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"},{"name":"Division of Hematology\u2013Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"},{"name":"Division of Hematology\u2013Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"},{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Toner","sequence":"additional","affiliation":[{"name":"Center for Bioengineering in Medicine, Massachusetts General Hospital and Shriners Hospital for Children, Harvard Medical School, Boston, MA 02114;"},{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-5120","authenticated-orcid":false,"given":"Kurt J.","family":"Isselbacher","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamala","family":"Maheswaran","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"},{"name":"Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Haber","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114;"},{"name":"Howard Hughes Medical Institute, Chevy Chase, MD 20815"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman PB","year":"2011","unstructured":"PB Chapman, , Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med; BRIM-3 Study Group 364, 2507\u20132516 (2011).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty KT","year":"2012","unstructured":"KT Flaherty, , Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med; METRIC Study Group 367, 107\u2013114 (2012).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild A","year":"2012","unstructured":"A Hauschild, , Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358\u2013365 (2012).","journal-title":"Lancet"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","unstructured":"FS Hodi, , Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711\u2013723 (2010).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert C","year":"2011","unstructured":"C Robert, , Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364, 2517\u20132526 (2011).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert C","year":"2014","unstructured":"C Robert, , Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109\u20131117 (2014).","journal-title":"Lancet"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert C","year":"2015","unstructured":"C Robert, , Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372, 320\u2013330 (2015).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"C Robert, , Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med; KEYNOTE-006 investigators 372, 2521\u20132532 (2015).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf D","year":"2015","unstructured":"D Schadendorf, , Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33, 1889\u20131894 (2015).","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian SL","year":"2014","unstructured":"SL Topalian, , Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32, 1020\u20131030 (2014).","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi FS","year":"2016","unstructured":"FS Hodi, , Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34, 1510\u20131517 (2016).","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"J Larkin, , Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373, 23\u201334 (2015).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_13_2","first-page":"39","article-title":"Prognostic and predictive markers for the new immunotherapies","volume":"28","author":"Mahoney KM","year":"2014","unstructured":"KM Mahoney, MB Atkins, Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28, 39\u201348 (2014).","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo W","year":"2016","unstructured":"W Hugo, , Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud AI","year":"2016","unstructured":"AI Daud, , Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 34, 4102\u20134109 (2016).","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le DT","year":"2015","unstructured":"DT Le, , PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372, 2509\u20132520 (2015).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi NA","year":"2015","unstructured":"NA Rizvi, , Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher TN","year":"2015","unstructured":"TN Schumacher, RD Schreiber, Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson DB","year":"2016","unstructured":"DB Johnson, , Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res 4, 959\u2013967 (2016).","journal-title":"Cancer Immunol Res"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh PC","year":"2014","unstructured":"PC Tumeh, , PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201010021","article-title":"Circulating tumor cells: Approaches to isolation and characterization","volume":"192","author":"Yu M","year":"2011","unstructured":"M Yu, S Stott, M Toner, S Maheswaran, DA Haber, Circulating tumor cells: Approaches to isolation and characterization. J Cell Biol 192, 373\u2013382 (2011).","journal-title":"J Cell Biol"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201303698","article-title":"Biology, detection, and clinical implications of circulating tumor cells","volume":"7","author":"Joosse SA","year":"2015","unstructured":"SA Joosse, TM Gorges, K Pantel, Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med 7, 1\u201311 (2015).","journal-title":"EMBO Mol Med"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.celrep.2014.03.039","article-title":"Isolation and molecular characterization of circulating melanoma cells","volume":"7","author":"Luo X","year":"2014","unstructured":"X Luo, , Isolation and molecular characterization of circulating melanoma cells. Cell Rep 7, 645\u2013653 (2014).","journal-title":"Cell Rep"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"179ra47","DOI":"10.1126\/scitranslmed.3005616","article-title":"Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells","volume":"5","author":"Ozkumur E","year":"2013","unstructured":"E Ozkumur, , Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5, 179ra47 (2013).","journal-title":"Sci Transl Med"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.celrep.2014.08.029","article-title":"Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells","volume":"8","author":"Ting DT","year":"2014","unstructured":"DT Ting, , Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep 8, 1905\u20131918 (2014).","journal-title":"Cell Rep"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.aab0917","article-title":"RNA-seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance","volume":"349","author":"Miyamoto DT","year":"2015","unstructured":"DT Miyamoto, , RNA-seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 349, 1351\u20131356 (2015).","journal-title":"Science"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1073\/pnas.1617032114","article-title":"An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma","volume":"114","author":"Kalinich M","year":"2017","unstructured":"M Kalinich, , An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci USA 114, 1123\u20131128 (2017).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria","volume":"15","author":"Wolchok JD","year":"2009","unstructured":"JD Wolchok, , Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15, 7412\u20137420 (2009).","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molonc.2015.12.008","article-title":"Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients","volume":"10","author":"Huang SK","year":"2016","unstructured":"SK Huang, DS Hoon, Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol 10, 450\u2013463 (2016).","journal-title":"Mol Oncol"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1373\/clinchem.2004.045096","article-title":"Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: Relation to disease stage in melanoma patients","volume":"51","author":"Koyanagi K","year":"2005","unstructured":"K Koyanagi, , Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: Relation to disease stage in melanoma patients. Clin Chem 51, 981\u2013988 (2005).","journal-title":"Clin Chem"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.1995.13.11.2769","article-title":"Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination","volume":"13","author":"Krismann M","year":"1995","unstructured":"M Krismann, , Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 13, 2769\u20132775 (1995).","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow MA","year":"2015","unstructured":"MA Postow, , Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372, 2006\u20132017 (2015).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"DB Johnson, , Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375, 1749\u20131755 (2016).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee JH","year":"2017","unstructured":"JH Lee, , Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 28, 1130\u20131136 (2017).","journal-title":"Ann Oncol"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2340\/00015555-2748","article-title":"Circulating tumour DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients","volume":"97","author":"Ashida A","year":"2017","unstructured":"A Ashida, K Sakaizawa, H Uhara, R Okuyama, Circulating tumour DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients. Acta Derm Venereol 97, 1212\u20131218 (2017).","journal-title":"Acta Derm Venereol"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder A","year":"2013","unstructured":"A Giobbie-Hurder, RD Gelber, MM Regan, Challenges of guarantee-time bias. J Clin Oncol 31, 2963\u20132969 (2013).","journal-title":"J Clin Oncol"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1719264115","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1719264115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T13:19:30Z","timestamp":1654607970000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1719264115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,3,6]]}},"alternative-id":["10.1073\/pnas.1719264115"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1719264115","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,16]]},"assertion":[{"value":"2018-02-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}